Sanofi and Regeneron Announce Approval of DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union Sanofi and Regeneron Announce Approval of DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union Paris, France and Tarrytown, New York - September 28, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for DupixentA , for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
http://ift.tt/2wYgz3R
No comments:
Post a Comment